Deng Yan, Yu Haopeng, Zins Marc, Zhang Xueying, Duan Xiuping, Zhang Xiaoming, Zhang Yi, Cao Dan, Huang Zixing, Song Bin
Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.
Sichuan Key Laboratory of Medical Imaging and Department of Radiology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
Eur Radiol. 2025 May 2. doi: 10.1007/s00330-025-11632-y.
To develop a score system including CT features for predicting postoperative early (≤ 1 year) recurrence-free survival (RFS) in resectable pancreatic ductal adenocarcinoma (PDAC) patients who underwent radical resection and assess its performance.
This dual-center, retrospective study included patients with resectable PDAC who underwent radical resection from September 2016 to April 2023. All CT features were independently evaluated by two blinded radiologists. An early recurrence score (ERS) based on CT and clinical features, for predicting early recurrence risk, was developed by Cox regression analysis in the developing cohort, and was validated in the testing and validation cohorts and compared with AJCC TNM staging system.
This study included 210 patients in the development cohort (mean age ± standard deviation, 60 ± 10 years; 129 men), 92 patients in the testing cohort (60 ± 9 years; 60 men), and 31 patients in the validation cohort (62 ± 7 years; 20 men). CA19-9 (hazard ratio [HR], 1.57; p = 0.044), perineural invasion on CT (HR, 1.83; p = 0.037), tumor necrosis (HR, 3.20; p < 0.001), and lymph nodes metastasis on CT (HR, 1.84; p = 0.004) formed the ERS. Its AUC of 0.851 and 0.901, superior to AJCC TNM staging (AUC of 0.630 and 0.534) in the testing and validation cohorts, (p < 0.05), respectively. The high-risk patients predicted by ERS had significantly higher postoperative 1-year recurrence rates than their low-risk counterparts in both the testing cohort (81.4% vs 22.5%, p < 0.001) and the validation cohort (81.2% vs 26.7%, p = 0.003).
The ERS noninvasively predicted early recurrence in resectable PDAC, outperforming the AJCC TNM system.
Question More accurately risk-stratifying PDAC patients would allow for better treatment planning. Findings Perineural invasion on CT, lymph nodes metastasis on CT, tumor necrosis, and CA19-9 were associated with early recurrence of resectable PDAC. Clinical relevance The ERS system showed better predictive performance for early recurrence in resectable PDAC and outperformed the American Joint Commission on Cancer TNM system.
建立一个包含CT特征的评分系统,用于预测接受根治性切除的可切除性胰腺导管腺癌(PDAC)患者术后早期(≤1年)无复发生存期(RFS),并评估其性能。
这项双中心回顾性研究纳入了2016年9月至2023年4月期间接受根治性切除的可切除性PDAC患者。所有CT特征均由两名盲法放射科医生独立评估。在开发队列中通过Cox回归分析建立了基于CT和临床特征的早期复发评分(ERS),用于预测早期复发风险,并在测试和验证队列中进行验证,并与美国癌症联合委员会(AJCC)TNM分期系统进行比较。
本研究包括开发队列中的210例患者(平均年龄±标准差,60±10岁;男性129例)、测试队列中的92例患者(60±9岁;男性60例)和验证队列中的31例患者(62±7岁;男性20例)。CA19-9(风险比[HR],1.57;p = 0.044)、CT上的神经周围侵犯(HR,1.83;p = 0.037)、肿瘤坏死(HR,3.20;p < 0.001)和CT上的淋巴结转移(HR,1.84;p = 0.004)构成了ERS。在测试和验证队列中,其AUC分别为0.851和0.901,优于AJCC TNM分期(AUC分别为0.630和0.534),(p < 0.05)。在测试队列(81.4% vs 22.5%,p < 0.001)和验证队列(81.2% vs 26.7%,p = 0.003)中,ERS预测的高危患者术后1年复发率均显著高于低危患者。
ERS可无创预测可切除性PDAC的早期复发,性能优于AJCC TNM系统。
问题更准确地对PDAC患者进行风险分层有助于更好地制定治疗计划。发现CT上的神经周围侵犯、CT上的淋巴结转移、肿瘤坏死和CA19-9与可切除性PDAC的早期复发相关。临床意义ERS系统在预测可切除性PDAC早期复发方面表现出更好的性能,优于美国癌症联合委员会TNM系统。